Phospho-c-Myc (Ser62) Antibody

About the Target

BCAR1 is a target of interest in many antibody-based workflows. Phospho-c-Myc (Ser 62) is a highly conserved, ubiquitously expressed transcription factor critical for regulating cell proliferation, growth, metabolism, and apoptosis, and is frequently overexpressed or dysregulated in a wide range of human cancers including lung, breast, colon, and hematopoietic malignancies. Structurally, c-Myc contains a transactivation domain at the N-terminus, where serine 62 (Ser-62) resides, and a C-terminal basic helix-loop-helix leucine zipper (bHLH-LZ) domain responsible for DNA binding and dimerization with its partner Max. Depending on the literature source, BCAR1 may also be discussed as Phospho-c-Myc (Ser62) and p130 Cas.

Reported cellular context includes cytoplasm and nucleus, which can matter when signal is compared across treatments or changing cell states. Following BCAR1 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

BCAR1 is commonly interpreted in the context of cancer research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cytoplasm and nucleus, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cytoplasm and nucleus across matched conditions
• changes associated with proliferative state, oncogenic signaling, or treatment response
• differences between total target abundance and site-specific regulation when modified forms are compared
• co-patterning with orthogonal markers and control conditions that clarify pathway state

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for BCAR1. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in BCAR1 reflect biology rather than handling. When interpreting BCAR1, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep BCAR1 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.